Valeant Returns $1bn Female Libido Drug For Free
Executive Summary
At first glance, giving back Addyi to the original owners for next to nothing looks like a complete disaster but investors are relieved debt-ridden Valeant has managed to offload another asset.
You may also be interested in...
10 Drug Launch Flops Of The Decade
The view from 2020: Scrip looks back over the last decade at the drug launches that defied expectations – for the worse.
AMAG Must Build Market For Approved Female Libido Drug To Avoid Addyi’s Fate
AMAG Pharmaceutical’s HSDD drug Vyleesi, has been approved by the FDA. But analysts warn it must build the market in women who may not be aware they have a condition if it is to fare better than Sprout’s Addyi.
US FDA Squashes Sprout's Attempt To Remove Boxed Warning From Addyi Label
In sharp disagreement, FDA says postmarketing trial shows risk of taking alcohol with the female sexual dysfunction drug; Sprout will appeal agency's decision.